Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nippon-shinyaku-co-ltd" target="_blank" data-smartkarma-citation="entities:6634:1" rel="noopener">Nippon Shinyaku (4516 JP)</a> and <a href="https://www.smartkarma.com/entities/capricor-therapeutics-inc" target="_blank" data-smartkarma-citation="entities:37671:1" rel="noopener">Capricor Therapeutics (CAPR US)</a> announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel.  </li>
<li>Capricor plans to submit its response to the Complete Response Letter incorporating HOPE-3 data, following prior alignment with FDA.</li>
<li>The next big trigger for the stock would be the approval of Deramiocel and RGX-121 by FDA followed by their commercialization.</li>
</ul>



Nippon Shinyaku (4516 JP) and Capricor Therapeutics (CAPR US) announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel.  
Capricor plans to submit its response to the Complete Response Letter incorporating HOPE-3 data, following prior alignment with FDA.
The next big trigger for the stock would be the approval of Deramiocel and RGX-121 by FDA followed by their commercialization.


Nippon Shinyaku (4516 JP): Deramiocel Data Positive, Approval and Commercialization Next Big Trigger

<ul>
<li>In 1QFY26, <a href="https://www.smartkarma.com/entities/nippon-shinyaku-co-ltd" target="_blank" data-smartkarma-citation="entities:6634:1" rel="noopener">Nippon Shinyaku (4516 JP)</a> revenue grew 1% YoY to ¥39.5B and operating profit stood at ¥10.1B (down 9% YoY) as company incurred forex losses.</li>
<li>Viltepso witnessed slowing in US. Licensing income increased on higher overseas sales of Uptravi. Newly launched drugs like Vyxeos and Fintepla showed promise.</li>
<li>FY26 guidance revised downwards taking into account FDA’s rejection of BLA for CAP-1002. The company reduced FY26 revenue guidance to ¥166B from ¥173B.</li>
</ul>


In 1QFY26, Nippon Shinyaku (4516 JP) revenue grew 1% YoY to ¥39.5B and operating profit stood at ¥10.1B (down 9% YoY) as company incurred forex losses.
Viltepso witnessed slowing in US. Licensing income increased on higher overseas sales of Uptravi. Newly launched drugs like Vyxeos and Fintepla showed promise.
FY26 guidance revised downwards taking into account FDA’s rejection of BLA for CAP-1002. The company reduced FY26 revenue guidance to ¥166B from ¥173B.


Nippon Shinyaku (4516 JP): Flurry of Concerns Going Ahead; Revenue Steady for Now; Guidance Revised

Hisamitsu Pharmaceutical Co / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> Q1FY26 revenue of ¥34.7B down 3% YoY, mainly driven by subdued performance in Salonpas focused OTC pharmaceutical products.</li>
<li>Rx business revenues grew 7% as Zicthoru, Apohide, Combipatch,Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.</li>
<li>Hisamitsu reiterated FY26 guidance expecting revenue to be ¥165B with profits growth expected to decelerate on higher cost.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) Q1FY26 revenue of ¥34.7B down 3% YoY, mainly driven by subdued performance in Salonpas focused OTC pharmaceutical products.
Rx business revenues grew 7% as Zicthoru, Apohide, Combipatch,Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.
Hisamitsu reiterated FY26 guidance expecting revenue to be ¥165B with profits growth expected to decelerate on higher cost.


Hisamitsu Pharmaceutical (4530 JP): Guidance Reiterated Amid Seemingly Temporary Hiccup in Q1FY26

<ul>
<li>In FY25, <a href="https://www.smartkarma.com/entities/nippon-shinyaku-co-ltd" target="_blank" data-smartkarma-citation="entities:6634:1" rel="noopener">Nippon Shinyaku (4516 JP)</a> revenue grew 8% YoY to ¥160B and operating profit stood at ¥35.5B, up 6.5%.</li>
<li>Viltepso witnessed growth both in Japan and the U.S., licensing income also increased on higher overseas sales of Uptravi. Newly launched drugs like Vyxeos and Fintepla showed promise.</li>
<li>FY26 guidance indicate forex headwinds as higher costs will dent margins.</li>
</ul>


In FY25, Nippon Shinyaku (4516 JP) revenue grew 8% YoY to ¥160B and operating profit stood at ¥35.5B, up 6.5%.
Viltepso witnessed growth both in Japan and the U.S., licensing income also increased on higher overseas sales of Uptravi. Newly launched drugs like Vyxeos and Fintepla showed promise.
FY26 guidance indicate forex headwinds as higher costs will dent margins.


Nippon Shinyaku (4516 JP): Stable FY25; New Launches Key; Guidance Indicates A Forex Wary FY26

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> reported double digit revenue growth in FY25 on the back of 16% YoY growth in Salonpas focused OTC pharmaceutical products.</li>
<li>Rx business revenues grew 5% YoY as Zicthoru, Apohide, Combipatch, Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.</li>
<li>Hisamitsu expects FY26 revenue to be ¥165B, up 6% YoY, driven by new products, with net profit growth to decelerate on higher cost.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) reported double digit revenue growth in FY25 on the back of 16% YoY growth in Salonpas focused OTC pharmaceutical products.
Rx business revenues grew 5% YoY as Zicthoru, Apohide, Combipatch, Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.
Hisamitsu expects FY26 revenue to be ¥165B, up 6% YoY, driven by new products, with net profit growth to decelerate on higher cost.


Hisamitsu Pharmaceutical (4530 JP): Salonpas Holds Fort; New Products Ramp-Up; Stable FY26 Expected

Japan

HISAMITSU PHARMACEUTICAL CO., INC. produces and sells pharmaceutical products. The Company's main product is anti-inflammatory analgesic plasters and poultices sold under the brand name Salonpas.  Hisamitsu Pharmaceutical exports its products to North America and Southeast Asia.  The Company also researches and develops antibacterial products through its related company, RRF.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hisamitsu Pharmaceutical Co (4530 JP)

Nippon Shinyaku (4516 JP): Deramiocel Data Positive, Approval and Commercialization Next Big Trigger

Nippon Shinyaku and Capricor announce positive Phase 3 results for Deramiocel, with potential FDA approval and commercialization on the horizon....

Tina Banerjee

Nippon Shinyaku (4516 JP): Flurry of Concerns Going Ahead; Revenue Steady for Now; Guidance Revised

Nippon Shinyaku reports mixed 1QFY26 result, with revenue growing 1% YoY and operating profit decreasing 9% YoY due to forex losses. The company...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Guidance Reiterated Amid Seemingly Temporary Hiccup in Q1FY26

Hisamitsu's Q1FY26 revenue was down 3% YoY due to subdued performance in Salonpas OTC products. However, FY26 guidance was reiterated as Salonpas...

Tina Banerjee

Nippon Shinyaku (4516 JP): Stable FY25; New Launches Key; Guidance Indicates A Forex Wary FY26

Nippon Shinyaku sees 8% revenue growth in FY25 on continued strength of Viltepso. Newly launched drugs showed promise. However, FY26 guidance...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Salonpas Holds Fort; New Products Ramp-Up; Stable FY26 Expected

Hisamitsu reported double-digit revenue growth in FY25 driven by Salonpas OTC products. The company expects 6% revenue growth in FY26 with net...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Nippon Shinyaku (4516 JP): Deramiocel Data Positive, Approval and Commercialization Next Big Trigger

​Nippon Shinyaku and Capricor announce positive Phase 3 results for Deramiocel, with potential FDA approval and commercialization on the horizon....

Tina Banerjee

Nippon Shinyaku (4516 JP): Flurry of Concerns Going Ahead; Revenue Steady for Now; Guidance Revised

​Nippon Shinyaku reports mixed 1QFY26 result, with revenue growing 1% YoY and operating profit decreasing 9% YoY due to forex losses. The company...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Guidance Reiterated Amid Seemingly Temporary Hiccup in Q1FY26

​Hisamitsu's Q1FY26 revenue was down 3% YoY due to subdued performance in Salonpas OTC products. However, FY26 guidance was reiterated as Salonpas...

Tina Banerjee

Nippon Shinyaku (4516 JP): Stable FY25; New Launches Key; Guidance Indicates A Forex Wary FY26

​Nippon Shinyaku sees 8% revenue growth in FY25 on continued strength of Viltepso. Newly launched drugs showed promise. However, FY26 guidance...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Salonpas Holds Fort; New Products Ramp-Up; Stable FY26 Expected

​Hisamitsu reported double-digit revenue growth in FY25 driven by Salonpas OTC products. The company expects 6% revenue growth in FY26 with net...

Tina Banerjee

Nippon Shinyaku and Capricor announce positive Phase 3 results for Deramiocel, with potential FDA approval and commercialization on the horizon....

Nippon Shinyaku reports mixed 1QFY26 result, with revenue growing 1% YoY and operating profit decreasing 9% YoY due to forex losses. The company...

Hisamitsu's Q1FY26 revenue was down 3% YoY due to subdued performance in Salonpas OTC products. However, FY26 guidance was reiterated as Salonpas...

Nippon Shinyaku sees 8% revenue growth in FY25 on continued strength of Viltepso. Newly launched drugs showed promise. However, FY26 guidance...

Hisamitsu reported double-digit revenue growth in FY25 driven by Salonpas OTC products. The company expects 6% revenue growth in FY26 with net...